Table 1 Demographic and main clinical measures of bvFTD patients and controls

From: Mapping the brain atrophy mediating increased impatience for reward in frontotemporal dementia

 

bvFTD

Controls

bvFTD vs. controls

% women

36.4%

52.9%

χ2 = 0.5; p = 0.48

Age

66.5 (8.5)

62.2 (7.2)

W = 256; p = 0.05

Age range

[45; 82]

[46; 71]

_

Education level

6.1 (2.0)

7.2 (1.1)

W = 136; p = 0.13

MMSE (/30)

23.8 (2.6)

29.5 (0.7)

W = 5.5; p < 0.001

DRS (/144)

119.4 (8.9)

142.2 (1.3)

W = 0; p < 0.001

Hayling (errors)

19.8 (13.7)

3.3 (2.5)

W = 331.5; p < 0.001

FAB (/18)

12.1 (3.4)

17.4 (0.9)

W = 6.5; p < 0.001

EBI (/32)

13.1 (6.2)

1.4 (1.9)

W = 360; p < 0.001

DAS-Executive (/24)

10.0 (4.6)

4.2 (3.6)

W = 311.5; p < 0.001

  1. Data are given as mean (SD). BvFTD patients: N = 22/controls: N = 17. For comparison, we used Wilcoxon tests for non-normally distributed variables and Student’s t-tests for normally distributed variables. First, the main clinical measures are listed.
  2. MMSE mini-mental state examination, DRS dementia rating scale. Second, variables of interest in the study are presented, Hayling (errors) objective measure of inhibition deficit from the Hayling Sentence Completion Test (number of errors in the inhibition phase of the test), FAB frontal assessment battery, EBI eating behaviour inventory, global measure of changes in eating behaviour, DAS-Exe dimensional apathy scale, subscale measuring lack of executive functions to complete goal-directed behaviours.
Back to article page